Orexo Drug Patent Portfolio
Orexo owns 1 orange book drug protected by 11 US patents Given below is the list of Orexo's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10874661 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US10946010 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US11020387 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US11020388 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US11433066 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US8940330 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US9259421 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US9439900 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | 18 Sep, 2032 | Active |
| US8470361 | Non-abusable pharmaceutical composition comprising opioids | 22 May, 2030 | Active |
| US8658198 | Non-abusable pharmaceutical composition comprising opioids | 03 Dec, 2027 | Active |
| US8454996 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
Latest Legal Activities on Orexo's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Orexo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Jun, 2024 | US10874661 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9439900 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Aug, 2023 | US9259421 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 06 Sep, 2022 | US11433066 |
|
Recordation of Patent Grant Mailed
Critical
| 06 Sep, 2022 | US11433066 |
|
Email Notification
Critical
| 18 Aug, 2022 | US11433066 |
|
Issue Notification Mailed
Critical
| 17 Aug, 2022 | US11433066 |
|
Application Is Considered Ready for Issue
Critical
| 28 Jul, 2022 | US11433066 |
| Dispatch to FDC | 28 Jul, 2022 | US11433066 |
|
Issue Fee Payment Received
Critical
| 26 Jul, 2022 | US11433066 |
|
Issue Fee Payment Verified
Critical
| 26 Jul, 2022 | US11433066 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jul, 2022 | US8940330 (Litigated) |
|
Mail Notice of Allowance
Critical
| 27 Apr, 2022 | US11433066 |
|
Email Notification
Critical
| 27 Apr, 2022 | US11433066 |
|
Electronic Review
Critical
| 27 Apr, 2022 | US11433066 |
Orexo Drug Patents' Oppositions Filed in EPO
Orexo drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 06, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP07824784A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12775283A | Dec, 2015 | Generics (U.K.) Limited | Opposition procedure closed |
| EP07824784A | Aug, 2014 | Generics [UK] Limited | Opposition rejected |
Orexo's Family Patents
Orexo drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 31.6% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Orexo Drug List
Given below is the complete list of Orexo's drugs and the patents protecting them.
1. Zubsolv
Zubsolv is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10874661 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US10946010 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US11020387 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US11020388 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US11433066 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US8940330 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US9259421 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US9439900 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
18 Sep, 2032
(6 years from now)
| Active |
| US8470361 | Non-abusable pharmaceutical composition comprising opioids |
22 May, 2030
(4 years from now)
| Active |
| US8658198 | Non-abusable pharmaceutical composition comprising opioids |
03 Dec, 2027
(1 year, 10 months from now)
| Active |
| US8454996 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zubsolv's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List